


PRODUCT INFORMATION



Rivastigmine-d₆ (tartrate)

Item No. 25633

CAS Registry No.: 194930-00-2
Formal Name: (S)-ethylmethyl-carbamic acid, 3-[1-[di(methyl-d₃)amino]ethyl]phenyl ester, 2R,3R-dihydroxybutanedioate
MF: C₁₄H₁₆D₆N₂O₂ • C₄H₆O₆
FW: 406.5
Chemical Purity: ≥98% (Rivastigmine)
Deuterium Incorporation: ≥99% deuterated forms (d₁-d₆); ≤1% d₀
Supplied as: A solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Rivastigmine-d₆ (tartrate) is intended for use as an internal standard for the quantification of rivastigmine (Item No. 14270) by GC- or LC-MS. The accuracy of the sample weight in this vial is between 5% over and 2% under the amount shown on the vial. If better precision is required, the deuterated standard should be quantitated against a more precisely weighed unlabeled standard by constructing a standard curve of peak intensity ratios (deuterated *versus* unlabeled).

Rivastigmine-d₆ (tartrate) is supplied as solid. A stock solution may be made by dissolving the rivastigmine-d₆ (tartrate) in the solvent of choice, which should be purged with an inert gas. Rivastigmine-d₆ (tartrate) is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF). The solubility of rivastigmine-d₆ (tartrate) in ethanol and DMSO is approximately 16 mg/ml and approximately 25 mg/ml in DMF.

Description

Rivastigmine is a cholinesterase (ChE) inhibitor that inhibits butyryl ChE (BChE) and acetyl ChE (AChE; IC₅₀s = 0.037 and 4.15 μM, respectively).¹ It increases levels of secreted amyloid precursor protein (sAPP) and decreases levels of soluble amyloid-β (1-40) and various N-terminal cleavage products in primary embryonic rat neurons undergoing degeneration when used at concentrations of 5 and 10 μM.² In a rat model of Alzheimer's disease induced by aluminum chloride (AlCl₃), rivastigmine (1 mg/kg per day) inhibits formation of amyloid plaques in brain sections and increases in AChE, IL-1β, and β-secretase 1 (BACE1) mRNA expression in the cerebral cortex.³ It inhibits AlCl₃-induced increases in escape latency time in the Morris water maze in a rat model of Alzheimer's disease when administered at a dose of 1 mg/kg. Rivastigmine (2 mg/kg) also reverses decreases in time spent in the open arms of an elevated plus maze, exploration time of a novel object in a novel object recognition test, and sucrose intake in a rat model of chronic mild stress.⁴ Formulations containing rivastigmine have been used in the treatment of dementia associated with Alzheimer's disease and Parkinson's disease.

References

1. Yu, Q.S., Zhu, X., Holloway, H.W., *et al.* *J. Med. Chem.* **45**(17), 3684-3691 (2002).
2. Bailey, J.A., Ray, B., Greig, N.H., *et al.* *PLoS One* **6**(7), e21954 (2011).
3. Ismail, M.F., Elmeshad, A.N., and Salem, N.A. *Int. J. Nanomedicine* **8**, 393-406 (2013).
4. Papp, M., Gruca, P., Lason-Tyburkiewicz, M., *et al.* *Psychopharmacology (Berl)* **233**(7), 1235-1243 (2016).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 11/28/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM